Segment & Geographic Data Quant-Grade Normalized (live API) API & CSV Delivery

Organon And Co's Business Segments

Organon And Co's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.

Segment Data As of FY
Reportable Segments
87
Per the company's own filing, this quarter
Largest Segment
Int l
75.5% of revenue
Total Revenue
$ 1,460
Consolidated, this quarter
Regions Reported
3
Geographic regions, this quarter
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/OGN/segments
https://api.csimarket.com/api/v1/companies/OGN/geographic
https://api.csimarket.com/api/v1/companies/OGN/exposure
Programmatic access for models, analytics, and integration workflows.
Dataset & schema
https://api.csimarket.com/api/datasets/business_segments
https://api.csimarket.com/api/schema/business_segments
https://api.csimarket.com/api/meta/business_segments

Revenue Share by Reportable Segment - FY

76%largest
  • Int l75.5%
  • U S24.5%
  • Nexplanon Implanon NXT13.8%
  • U S Nexplanon Implanon NXT8.7%
  • Zetia6%
  • Int l Zetia5.9%
  • Int l Atozet5.8%
  • Int l Other5.8%
  • Atozet5.8%
  • Int l Nexplanon Implanon NXT5.1%
  • Other Non-Opiod Pain Bone and Dermatology4.7%
  • Hadlima4.6%
  • Int l Nasonex4.5%
  • Int l Other Non-Opiod Pain Bone and Dermatology4.5%
  • Nasonex4.5%
  • Follistim AQ4.2%
  • Int l Arcoxia4%
  • Arcoxia4%
  • Renflexis3.9%
  • Cozaar Hyzaar3.9%
  • Int l Cozaar Hyzaar3.8%
  • Int l Emgality3.7%
  • Emgality3.7%
  • U S Hadlima3.5%
  • Other Women s Health3.2%
  • U S Renflexis2.9%
  • Singulair2.7%
  • Int l Follistim AQ2.7%
  • Int l Singulair2.6%
  • Int l Diprospan2.4%
  • Dulera2.4%
  • Diprospan2.4%
  • Clarinex2.1%
  • Int l Other Women s Health2.1%
  • Int l Clarinex2.1%
  • Propecia2.1%
  • Int l Fosamax2%
  • Fosamax2%
  • Int l Propecia1.9%
  • Other Cardiovascular1.9%
  • Int l Other Cardiovascular1.8%
  • Int l Marvelon Mercilon1.8%
  • Int l Proscar1.8%
  • Ganirelix Acetate Injection1.8%
  • Marvelon Mercilon1.8%
  • Proscar1.8%
  • Vtama1.7%
  • Int l Ganirelix Acetate Injection1.6%
  • NuvaRing1.6%
  • Other Biosimilars1.6%
  • Other1.6%
  • U S Dulera1.6%
  • U S Vtama1.6%
  • Vytorin1.4%
  • U S Follistim AQ1.4%
  • Int l Brenzys1.4%
  • Int l Vytorin1.4%
  • Brenzys1.4%
  • Int l NuvaRing1.2%
  • U S Other Women s Health1.2%
  • Int l Hadlima1.1%
  • Int l Renflexis1%
  • Int l Other Biosimilars0.9%
  • Int l Dulera0.8%
  • Other Respiratory0.8%
  • U S Other Biosimilars0.8%
  • U S Other Respiratory0.8%
  • Int l Rosuzet0.4%
  • Rosuzet0.4%
  • U S NuvaRing0.4%
  • Jada0.3%
  • Ontruzant0.3%
  • U S Jada0.3%
  • U S Ontruzant0.3%
  • U S Other Non-Opiod Pain Bone and Dermatology0.2%
  • U S Other0.2%
  • Int l Vtama0.1%
  • U S Ganirelix Acetate Injection0.1%
  • U S Cozaar Hyzaar0.1%
  • U S Singulair0.1%
  • Int l Ontruzant0.1%
  • Int l Other Respiratory0.1%
  • U S Zetia0.1%
  • U S Vytorin0.1%
  • U S Other Cardiovascular0.1%
  • U S Clarinex0.1%
  • U S Propecia0.1%

Revenue by Reportable Segment - FY

SegmentPeriodRevenue
(Millions)
% of TotalOperating Income
Int lFY$ 1,10275.5%-
U SFY$ 35824.5%-
Nexplanon Implanon NXTFY$ 20113.8%-
84 more segments available

Sign in to unlock the full Organon And Co dataset.

Revenue Share by Region - FY

17%largest
  • Latin America, Middle East, Russia and Africa17.3%
  • Asia Pacific and Japan14.9%
  • Other Countries1.2%

Revenue by Geographic Region - FY

RegionPeriodRevenue
(Millions)
% of Total
Latin America, Middle East, Russia and AfricaFY$ 26917.3%
Asia Pacific and JapanFY$ 23214.9%
Other CountriesFY$ 191.2%

Revenue by Product & Service Category - FY

8%largest
  • Nexplanon/Implanon NXT8.3%
  • Atozet5.1%
  • Arcoxia4.4%
  • Nasonex3.7%
  • Hadlima3.5%
  • Emgality/Ravvow3.5%
  • Diprospan2.8%
  • Renflexis2.8%
  • Vtama2.2%
  • Marvelon/Mercilon2.1%
  • Dulera1.9%
  • Proscar1.3%
  • Follistim AQ1.1%
  • Other Respiratory1%
  • Other Womens Health1%
  • Brenzys0.9%
  • Other Sundry Products0.9%
  • Bildvos/Bilprevda0.9%
  • Other Biosimilars0.6%
  • NuvaRing0.6%
  • Rosuzet0.3%
  • Ontruzant0.3%
  • Other Non-Opiod Pain, Bone and Dermatology0.3%
  • Other Sundry Established Brands0.1%
  • Ganirelix Acetate Injection0.1%
  • Cozaar/Hyzaar0.1%
  • Propecia0.1%
  • Zetia0.1%
  • Singulair0.1%
  • Clarinex0.1%
  • Other Cardiovascular0.1%
  • Fosamax0.1%
  • Vytorin0.1%

Revenue by Product & Service Category - FY

CategoryPeriodRevenue
(Millions)
% of Total
Nexplanon/Implanon NXTFY$ 1298.3%
AtozetFY$ 805.1%
ArcoxiaFY$ 694.4%

Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.

30 more categories available

Sign in to unlock the full Organon And Co dataset.

Annual Results

Revenue Share by Reportable Segment - FY

76%largest
  • Int l75.5%
  • U S24.5%
  • Nexplanon Implanon NXT13.8%
  • U S Nexplanon Implanon NXT8.7%
  • Zetia6%
  • Int l Zetia5.9%
  • Int l Atozet5.8%
  • Int l Other5.8%
  • Atozet5.8%
  • Int l Nexplanon Implanon NXT5.1%
  • Other Non-Opiod Pain Bone and Dermatology4.7%
  • Hadlima4.6%
  • Int l Nasonex4.5%
  • Int l Other Non-Opiod Pain Bone and Dermatology4.5%
  • Nasonex4.5%
  • Follistim AQ4.2%
  • Int l Arcoxia4%
  • Arcoxia4%
  • Renflexis3.9%
  • Cozaar Hyzaar3.9%
  • Int l Cozaar Hyzaar3.8%
  • Int l Emgality3.7%
  • Emgality3.7%
  • U S Hadlima3.5%
  • Other Women s Health3.2%
  • U S Renflexis2.9%
  • Singulair2.7%
  • Int l Follistim AQ2.7%
  • Int l Singulair2.6%
  • Int l Diprospan2.4%
  • Dulera2.4%
  • Diprospan2.4%
  • Clarinex2.1%
  • Int l Other Women s Health2.1%
  • Int l Clarinex2.1%
  • Propecia2.1%
  • Int l Fosamax2%
  • Fosamax2%
  • Int l Propecia1.9%
  • Other Cardiovascular1.9%
  • Int l Other Cardiovascular1.8%
  • Int l Marvelon Mercilon1.8%
  • Int l Proscar1.8%
  • Ganirelix Acetate Injection1.8%
  • Marvelon Mercilon1.8%
  • Proscar1.8%
  • Vtama1.7%
  • Int l Ganirelix Acetate Injection1.6%
  • NuvaRing1.6%
  • Other Biosimilars1.6%
  • Other1.6%
  • U S Dulera1.6%
  • U S Vtama1.6%
  • Vytorin1.4%
  • U S Follistim AQ1.4%
  • Int l Brenzys1.4%
  • Int l Vytorin1.4%
  • Brenzys1.4%
  • Int l NuvaRing1.2%
  • U S Other Women s Health1.2%
  • Int l Hadlima1.1%
  • Int l Renflexis1%
  • Int l Other Biosimilars0.9%
  • Int l Dulera0.8%
  • Other Respiratory0.8%
  • U S Other Biosimilars0.8%
  • U S Other Respiratory0.8%
  • Int l Rosuzet0.4%
  • Rosuzet0.4%
  • U S NuvaRing0.4%
  • Jada0.3%
  • Ontruzant0.3%
  • U S Jada0.3%
  • U S Ontruzant0.3%
  • U S Other Non-Opiod Pain Bone and Dermatology0.2%
  • U S Other0.2%
  • Int l Vtama0.1%
  • U S Ganirelix Acetate Injection0.1%
  • U S Cozaar Hyzaar0.1%
  • U S Singulair0.1%
  • Int l Ontruzant0.1%
  • Int l Other Respiratory0.1%
  • U S Zetia0.1%
  • U S Vytorin0.1%
  • U S Other Cardiovascular0.1%
  • U S Clarinex0.1%
  • U S Propecia0.1%

Revenue by Reportable Segment - FY

SegmentPeriodRevenue
(Millions)
% of TotalOperating Income
Int lFY$ 1,10275.5%-
U SFY$ 35824.5%-
Nexplanon Implanon NXTFY$ 20113.8%-
84 more segments available

Sign in to unlock the full Organon And Co dataset.

Description of Organon And Co

Organon and Co is a pharmaceutical company that was founded nearly a century and a half ago in the Netherlands. It has since grown into a global biopharmaceutical company that specializes in developing and manufacturing innovative medicines to improve patients' lives.

The company's name, Organon, refers to the Greek word "organon," which means "tool" or "instrument." This reflects Organon's mission to create tools and solutions to help physicians and healthcare providers feel confident in their treatment decisions.

Organon and Co's focus is on three main areas: Women's Health, Biosimilars, and Established Brands. The Women's Health division focuses on developing and providing solutions for women's health and wellness, including contraception, infertility, and menopause treatments. The Biosimilars division aims to provide access to high-quality, affordable biosimilars, helping to increase patient access to life-saving biologic medicines. The Established Brands division focuses on providing innovative solutions to improve the health and well-being of patients, including treatments for cardiovascular disease, migraine, and schizophrenia.

Organon and Co is committed to advancing science and research to better understand and meet patients' needs. They invest heavily in research and development, focusing on developing innovative medicines and treatments using state-of-the-art technologies.

In addition to its focus on innovative research and development, Organon and Co is committed to social responsibility and sustainability. They have created programs and initiatives to promote health and wellness in underserved communities, reduce their environmental impact, and improve patient access to medicines.

Overall, Organon and Co's mission is to improve patients' lives by providing innovative solutions and treatments that address pressing medical needs. They are committed to advancing science and research, promoting social responsibility, and ensuring patient access to life-saving medicines.
Organon & Co: Extensive Overview of Segments, Products, and Services

Introduction:
Organon & Co is a prominent global healthcare company dedicated to improving the health and well-being of individuals across the globe. The company specializes in a diverse array of segments, products, and services designed to address various healthcare needs, reflecting their commitment to innovation, quality, and patient support.

Segments:

1. Women’s Health:
Organon & Co places a strong emphasis on Womens Health, addressing critical issues affecting womens health and well-being. This segment offers a broad spectrum of products that cater to various stages of a womans life:
- Contraception: A range of products provides reliable options for family planning.
- Fertility: Solutions aimed at assisting women in achieving pregnancy.
- Menopause: Products designed to manage the symptoms associated with menopause.
- Endometriosis: Treatments that aim to alleviate the impact of endometriosis on womens health.

2. Biosimilars:
The biosimilars segment offers biologic products that share similarities with existing biologics. These therapies are essential for treating complex medical conditions:
- Cancer Treatments: Addressing various forms of cancer with innovative therapies that reduce the burden on patients.
- Autoimmune Diseases: Products designed to manage conditions such as rheumatoid arthritis and psoriasis.
- Chronic Inflammation: Therapeutic solutions that help manage ongoing inflammatory conditions.

3. Established Brands:
This segment focuses on a portfolio of established generic pharmaceuticals. The established brands include:
- Pain Management: Effectively treating severe to moderate pain conditions.
- Cardiovascular: Medications that support cardiovascular health.
- Respiratory Products: Treatments for various respiratory ailments.

4. Oncology:
Organon & Co also has a robust oncology portfolio, offering innovative therapies for multiple types of cancer. Their approach incorporates cutting-edge technologies, including:
- Biologics: Targeted treatments harnessing the body’s immune system against cancer.
- Antibody-Drug Conjugates: Combining antibodies with cytotoxic agents to deliver targeted therapy directly to cancer cells.
- Small Molecules: Chemotherapy agents and targeted oral medications that play a pivotal role in cancer treatment.

Products and Services:

1. NuvaRing:
A hormonal contraceptive device that is a small, flexible ring inserted vaginally, providing contraception for up to three weeks. It releases a combination of hormones to prevent ovulation.

2. Follistim:
A follicle-stimulating hormone used primarily in assisted reproductive technology, such as in vitro fertilization (IVF), to stimulate the ovaries egg development.

3. Zoely:
A combined hormonal contraceptive pill that contains estradiol and nomegestrol, aiding in effective pregnancy prevention while regulating menstrual cycles.

4. LIVESTRONG Cancer Navigation:
A supportive service that offers free navigation for cancer patients and caregivers. This program connects individuals with personal navigators who help them understand treatment options, access resources, and manage the complexities of the healthcare system.

5. Gonal-f:
Another hormone product that aids in ovarian follicle development for women undergoing infertility treatments, enhancing the chances of conception in assisted reproductive procedures.

6. Bicalutamide:
An anti-androgen medication employed in the treatment of prostate cancer, working by inhibiting male hormones effects on prostate cells and ultimately leading to slower cancer growth.

Remicade Biosimilar:
A biosimilar offering that provides a cost-effective alternative to Remicade, used extensively in managing autoimmune disorders, helping make treatment more accessible to patients.

8. Implanon:
A long-acting hormonal contraceptive implant that is placed under the skin of the arm, providing up to three years of pregnancy protection through a continuous release of hormones.

Conclusion:
Organon & Co is committed to enhancing healthcare through a diverse portfolio that spans Women’s Health, biosimilars, established brands, and oncology. Their innovative products and supportive services prioritize the unique healthcare needs of women and cancer patients while offering effective treatments for a range of medical conditions. By focusing on quality and patient empowerment, Organon & Co plays a vital role in advancing global health and improving the quality of life for individuals around the world.